Loading…
Loading…
EQUITY / NASDAQ · XNCM
BioRestorative Therapies Inc.
01 / RESEARCH
8 financial reports are available for research.
Start research ↗2.33 USD · 0%
Observed: Sep 30, 2026, 8:00 PM · TickerLayer indicative price; may be delayed
Powered by TickerLayer
09/30/2026 · 2.33 USD · Volume 24,940
251 actual observations · Latest bar: 2026-09-30 · Market data is indicative; provider terms apply.
8 available financial reports
Research reports →SEC FINANCIAL REPORTS
01/01/2026 – 03/31/2026 · Units
| Metric | 2026 / Quarter 1 | 2025 / Quarter 1 | Change |
|---|---|---|---|
| Cash and cash equivalents | 3,112,679 USD | — | — |
| Financing cash flow | 4,440,836 USD | 1,092,718 USD | +306.40% |
| Gross profit | 15,785 USD | 22,091 USD | -28.55% |
| Investing cash flow | 968,447 USD | 2,366,967 USD | -59.08% |
| Net income | -2,154,405 USD | -5,339,799 USD | — |
Changes are calculated only for matching period length, consolidation, currency, and scale. Percentages are not shown for zero or negative baselines.
Each column uses its report's scale. Check column headers before comparing different consolidation scopes and scales.
| Financial metric | 2026 / Quarter 1ConsolidatedUnits · USD | 2025 / Quarter 1ConsolidatedUnits · USD | 2025 / Year endConsolidatedUnits · USD | 2025 / Quarter 3ConsolidatedUnits · USD | 2025 / Quarter 3ConsolidatedUnits · USD | 2025 / Quarter 3ConsolidatedUnits · USD | 2025 / Quarter 2ConsolidatedUnits · USD | 2025 / Quarter 1ConsolidatedUnits · USD |
|---|---|---|---|---|---|---|---|---|
| Cash and cash equivalentsBalance sheet | 3,112,679 USD | 1,511,188 USD | 1,511,188 USD | 602,444 USD | — | — | — | — |
| Financing cash flowCash flow statement | 4,440,836 USD | — | 2,854,791 USD | — | 1,931,548 USD | — | 1,980,856 USD | 1,092,718 USD |
| Gross profitIncome statement | 15,785 USD | — | 335,856 USD | 1,230 USD | 317,892 USD | — | 316,662 USD | 22,091 USD |
| Investing cash flowCash flow statement | 968,447 USD | — | 8,897,470 USD | — | 6,496,796 USD | — | 4,499,158 USD | 2,366,967 USD |
| Net incomeIncome statement | -2,154,405 USD | — | -14,241,975 USD | -3,038,277 USD | -11,034,339 USD | -2,656,263 USD | -7,996,062 USD | -5,339,799 USD |
| Operating cash flowCash flow statement | -3,807,792 USD | — | -10,788,963 USD | — | -8,373,790 USD | — | -5,472,653 USD | -2,778,786 USD |
| Operating profitIncome statement | -3,385,733 USD | — | -15,647,132 USD | -3,709,011 USD | -11,821,832 USD | — | -8,112,821 USD | -4,807,534 USD |
| RevenueIncome statement | 23,170 USD | — | 359,700 USD | 11,800 USD | 340,100 USD | — | 328,300 USD | 25,000 USD |
| Total assetsBalance sheet | 4,640,279 USD | 4,079,635 USD | 4,079,635 USD | 5,642,662 USD | — | — | — | — |
| Total equityBalance sheet | 3,025,642 USD | 356,744 USD | 356,744 USD | 2,206,979 USD | — | 4,845,324 USD | — | 6,144,741 USD |
| Capital expendituresCash flow statement | — | — | 116,069 USD | — | 36,400 USD | — | 36,400 USD | 36,400 USD |
| Report source | Open report ↗ Published: 05/14/2026 | Open report ↗ Published: 05/14/2026 | Open report ↗ Published: 03/26/2026 | Open report ↗ Published: 11/12/2025 | Open report ↗ Published: 11/12/2025 | Open report ↗ Published: 11/12/2025 | Open report ↗ Published: 08/12/2025 | Open report ↗ Published: 05/14/2026 |
The latest available source version is shown for each period. Previous versions and correction relationships are not shown in this view.